Key Studies Influencing My Practice Following EACS 2021—Audio Recap

In this episode, Tristan J. Barber, MA, MD, FRCP, discusses new HIV data from EACS 2021, including:

• First-line therapies
  • BIC/FTC/TAF in a test-and-treat model in IMEA 055 FAST
  • Week 144 data of ISL + DOR in treatment-naive patients from P011
• Switch Strategies
  • Data on the use of DTG/3TC in patients with an M184V mutation from SOLAR 3D and the French Dat’AIDS Cohort
• Long-Acting Therapies
  • Efficacy and safety of LA CAB + RPV by BMI
  • Long-term follow-up of participants who discontinued LA CAB + RPV in the ATLAS, ATLAS-2M, and FLAIR trials
  • Patient satisfaction with LA CAB + RPV from the CARISEL study
  • Resistance and subgroup data from the CAPELLA study of lenacapavir in heavily treatment–experienced patients
• COVID-19 vaccination efficacy and the impact of the pandemic on viral suppression in PWH

Presenter:

Tristan J. Barber, MA, MD, FRCP
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
Honorary Associate Professor
Institute for Global Health
University College London
London, United Kingdom

Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Merck Sharp & Dohme Corp; and ViiV Healthcare.

Follow along with an expanded slideset at:
https://bit.ly/32RCX4N

Link to full program:
https://bit.ly/3G2GknK

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.